11/21
08:27 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Mizuho from $99.00 to $103.00. They now have an "outperform" rating on the stock.
Medium
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its price target raised by analysts at Mizuho from $99.00 to $103.00. They now have an "outperform" rating on the stock.
11/20
11:12 am
cytk
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan [Yahoo! Finance]
Low
Report
Bayer Acquires Rights for Cardiovascular Drug From CYTK in Japan [Yahoo! Finance]
11/20
08:07 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Medium
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
11/19
08:45 am
cytk
Cytokinetics and Bayer partner to develop for aficamten in Japan [Seeking Alpha]
Low
Report
Cytokinetics and Bayer partner to develop for aficamten in Japan [Seeking Alpha]
11/19
05:39 am
cytk
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan [Yahoo! Finance]
Medium
Report
Cytokinetics Will Get More Revenue for Marketing Aficamten in Japan [Yahoo! Finance]
11/19
03:30 am
cytk
Bayer acquires rights to Cytokinetics' heart drug in Japan [Yahoo! Finance]
Low
Report
Bayer acquires rights to Cytokinetics' heart drug in Japan [Yahoo! Finance]
11/19
02:30 am
cytk
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
Low
Report
Cytokinetics and Bayer Announce Exclusive Licensing Collaboration for Aficamten in Japan
11/18
08:07 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Medium
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
11/16
09:03 am
cytk
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024 [Yahoo! Finance]
Medium
Report
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024 [Yahoo! Finance]
11/16
09:03 am
cytk
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024 [Yahoo! Finance]
Medium
Report
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024 [Yahoo! Finance]
11/16
09:00 am
cytk
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
Medium
Report
Cytokinetics Presents Additional Data From GALACTIC-HF at the American Heart Association Scientific Sessions 2024
11/16
09:00 am
cytk
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
Medium
Report
Cytokinetics Presents New Data Relating to Aficamten and Hypertrophic Cardiomyopathy at the American Heart Association Scientific Sessions 2024
11/12
04:00 pm
cytk
Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference
Low
Report
Cytokinetics to Participate in the 2024 Jefferies London Healthcare Conference
11/11
07:30 am
cytk
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089
Low
Report
Cytokinetics Announces Initiation of Phase 1 Clinical Study of CK-4015089
11/8
07:59 am
cytk
Cytokinetics Third Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
Low
Report
Cytokinetics Third Quarter 2024 Earnings: Misses Expectations [Yahoo! Finance]
11/7
04:11 pm
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
Medium
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $120.00 price target on the stock.
11/7
04:16 am
cytk
Cytokinetics Inc (CYTK) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]
Medium
Report
Cytokinetics Inc (CYTK) Q3 2024 Earnings Call Highlights: Strategic Advances Amid Financial ... [Yahoo! Finance]
11/6
06:28 pm
cytk
Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
Low
Report
Cytokinetics (CYTK) Reports Q3 Loss, Lags Revenue Estimates [Yahoo! Finance]
11/6
04:00 pm
cytk
Cytokinetics Reports Third Quarter 2024 Financial Results
Low
Report
Cytokinetics Reports Third Quarter 2024 Financial Results
11/5
04:00 pm
cytk
Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024
Medium
Report
Cytokinetics Announces Six Upcoming Presentations at the American Heart Association Scientific Sessions 2024
11/5
07:56 am
cytk
Earnings To Watch: Cytokinetics Inc (CYTK) Reports Q3 2024 Result [Yahoo! Finance]
Low
Report
Earnings To Watch: Cytokinetics Inc (CYTK) Reports Q3 2024 Result [Yahoo! Finance]
11/4
04:00 pm
cytk
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/23
04:00 pm
cytk
Cytokinetics to Announce Third Quarter Results on November 6, 2024
Low
Report
Cytokinetics to Announce Third Quarter Results on November 6, 2024
10/18
08:33 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
10/17
08:55 am
cytk
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.
Low
Report
Cytokinetics, Incorporated (NASDAQ: CYTK) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $72.00 price target on the stock.